香港 2026年7月7日,创胜集团医药-B(06628)公告称,公司通过全资子公司杭州奕安济世生物药业有限公司与礼来公司签署《第1号修订协议》,将LY-3108653及LY-2950913两项许可化合物及全部相关权利(统称“归还资产”)归还礼来,对价为4.0百万美元(约人民币27.22百万元,按2026年7月7日美元兑人民币汇率1:6.8054计算)。
香港 2026年7月7日,创胜集团医药-B(06628)公告称,公司通过全资子公司杭州奕安济世生物药业有限公司与礼来公司签署《第1号修订协议》,将LY-3108653及LY-2950913两项许可化合物及全部相关权利(统称“归还资产”)归还礼来,对价为4.0百万美元(约人民币27.22百万元,按2026年7月7日美元兑人民币汇率1:6.8054计算)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.